Business Context and Reporting Period
Company: Cocrystal Pharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 4, 2020
Reporting Period: Single event date (March 4, 2020)
Business Context: The Company is a Delaware corporation with its principal executive offices in Bothell, WA. Its common stock trades on The Nasdaq Capital Market under the symbol "COCP".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing discloses the posting of an investor presentation to the Company's website on March 4, 2020.
Guidance, Outlook, and Risks
- Management Commentary: The Company furnished an Investor Presentation dated March 2020 (Exhibit 99.1) to its website.
- Legal Status of Information: The information contained in Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It is not subject to liabilities under such section and shall not be incorporated by reference into any other filings.
- Emerging Growth Company: The registrant did not check the box to indicate it is an emerging growth company.
Investor Verification Checklist
- Verify the content of the Investor Presentation (Exhibit 99.1) posted on March 4, 2020, as the 8-K itself contains no financial data.
- Confirm the trading status of common stock (COCP) on The Nasdaq Capital Market.
- Note that the furnished presentation is not legally "filed" and carries different liability standards than standard SEC filings.